Glucagon-like peptide-1 receptor agonists, also known as GLP-1 agonists and GLP-1RAs, are a class of medications that activate the GLP-1 receptor, causing reduced blood sugar, reduced appetite, and reduced energy intake.
A significant disadvantage of using these medications is the high rate of weight regain when they are discontinued. Achieving success with pharmacologic treatment and then weaning to avoid future negative effects would be ideal. Keywords: treating obesity, GLP-1 receptor agonists...
Background: GLP-1 receptor agonists and related incretin-based therapies are effective pharmacological treatments for weight loss in adults with obesity and type 2 diabetes. However, weight regain after treatment discontinuation or attenuation remains a major clinical...
HealthDay News Adults with overweight or obesity regain much of their lost weight after cessation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), according to a review published online March 4 in eClinicalMedicine .
GLP-1 receptor agonists are key medications for type 2 diabetes and obesity, working to lower blood sugar and aid weight loss by reducing appetite. Always consult a healthcare provider before starting GLP-1s and combine them with a healthy diet and exercise for best results.
This particular example perfectly highlights why Glp-1 Receptor Agonists And Weight Regain is so captivating.
GLP-1 receptor agonists are commonly used as pharmacotherapy for weight loss in patients with obesity.
Although GLP-1 agonists have side effects, the weight loss benefits may outweigh their risks. Disclosure: Dr Sanders has no relevant financial disclosures. Darlene M. Sanders, DMSc, MPAS, PA-C, is a family practice PA in rural Montana.
